News

Nanotechnology Stock News: Sona (CSE: SONA) Discontinues Clinical Trial for COVID-19 Rapid Saliva Test

Halifax, Nova Scotia – June 11, 2021 (Newsfile Corp.) (Investorideas.com Newswire) Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) a developer of rapid, point-of-care diagnostic tests announces that it is discontinuing its previously announced clinical trial of its COVID-19 rapid, antigen saliva test after a review of the interim results data

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:News